Please assess the completion status of the following clinical trial:

Trial Title: Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen OIT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Ages 4 through 26 years, inclusive~* Clinical history of allergy to peanuts or peanut-containing foods~* Serum IgE to peanut \>0.35 kU/L (determined by UniCAP within the past 12 months) and/or a SPT to peanut \>3 mm compared to control~* Experience dose-limiting symptoms at or before the 100mg dose of peanut protein (measured as 200 mg of peanut flour) on abbreviated screening OFC conducted via PRACTALL guidelines~* Use of birth control by females of child-bearing potential~Key Exclusion Criteria:~* History of Cardiovascular disease~* History of frequent or repeated, severe or life-threatening episodes of anaphylactic shock~* History of other chronic disease~* History of eosinophilic gastrointestinal disease~* Severe asthma~* Mild or moderate asthma if uncontrolled~* Use of omalizumab within the past 6 months or current use of other non-traditional forms of allergen immunotherapy~* Use of beta-blockers(oral), angiotensin-converting enzyme (ACE)~* Pregnancy, lactation~* Having the same place of residence as another study subject~* Participation in an interventional clinical trial 30 days prior to randomization

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 26 Years
- Healthy Volunteers: f

Study Arms:
- AR101 powder provided in capsules (Type: EXPERIMENTAL): Study product provided as peanut protein in pull-apart capsules
- Placebo powder provided in capsules (Type: PLACEBO_COMPARATOR): Placebo formulation in pull-apart capsules containing only inactive ingredients

Based on this trial design, predict the completion outcome and termination type (if applicable).